164 related articles for article (PubMed ID: 33278864)
1. DNA methylation subtypes for ovarian cancer prognosis.
Yin L; Zhang N; Yang Q
FEBS Open Bio; 2021 Mar; 11(3):851-865. PubMed ID: 33278864
[TBL] [Abstract][Full Text] [Related]
2. Identification of metastasis and prognosis-associated genes for serous ovarian cancer.
Yang Y; Qi S; Shi C; Han X; Yu J; Zhang L; Qin S; Gao Y
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510146
[TBL] [Abstract][Full Text] [Related]
3. Identification three LncRNA prognostic signature of ovarian cancer based on genome-wide copy number variation.
Zheng M; Hu Y; Gou R; Nie X; Li X; Liu J; Lin B
Biomed Pharmacother; 2020 Apr; 124():109810. PubMed ID: 32000042
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer.
Mishra NK; Guda C
Oncotarget; 2017 Apr; 8(17):28990-29012. PubMed ID: 28423671
[TBL] [Abstract][Full Text] [Related]
5. Identification of prognostic signature of non-small cell lung cancer based on TCGA methylation data.
Wang Y; Wang Y; Wang Y; Zhang Y
Sci Rep; 2020 May; 10(1):8575. PubMed ID: 32444802
[TBL] [Abstract][Full Text] [Related]
6. A six-CpG-based methylation markers for the diagnosis of ovarian cancer in blood.
Wang L; Ni S; Du Z; Li X
J Cell Biochem; 2020 Feb; 121(2):1409-1419. PubMed ID: 31502352
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
[TBL] [Abstract][Full Text] [Related]
8. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
[TBL] [Abstract][Full Text] [Related]
9. Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel.
Cicek MS; Koestler DC; Fridley BL; Kalli KR; Armasu SM; Larson MC; Wang C; Winham SJ; Vierkant RA; Rider DN; Block MS; Klotzle B; Konecny G; Winterhoff BJ; Hamidi H; Shridhar V; Fan JB; Visscher DW; Olson JE; Hartmann LC; Bibikova M; Chien J; Cunningham JM; Goode EL
Hum Mol Genet; 2013 Aug; 22(15):3038-47. PubMed ID: 23571109
[TBL] [Abstract][Full Text] [Related]
10. RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.
Häfner N; Steinbach D; Jansen L; Diebolder H; Dürst M; Runnebaum IB
Int J Cancer; 2016 Jan; 138(1):217-28. PubMed ID: 26175272
[TBL] [Abstract][Full Text] [Related]
11. Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival.
Dai W; Teodoridis JM; Zeller C; Graham J; Hersey J; Flanagan JM; Stronach E; Millan DW; Siddiqui N; Paul J; Brown R
Clin Cancer Res; 2011 Jun; 17(12):4052-62. PubMed ID: 21459799
[TBL] [Abstract][Full Text] [Related]
12. Aberrant Hypomethylation of Solute Carrier Family 6 Member 12 Promoter Induces Metastasis of Ovarian Cancer.
Sung HY; Yang SD; Park AK; Ju W; Ahn JH
Yonsei Med J; 2017 Jan; 58(1):27-34. PubMed ID: 27873492
[TBL] [Abstract][Full Text] [Related]
13. Promoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian Cancer.
Ding JJ; Wang G; Shi WX; Zhou HH; Zhao EF
Reprod Sci; 2016 Jan; 23(1):24-30. PubMed ID: 26507869
[TBL] [Abstract][Full Text] [Related]
14. Molecular subtypes based on DNA promoter methylation predict prognosis in lung adenocarcinoma patients.
Shi S; Xu M; Xi Y
Aging (Albany NY); 2020 Nov; 12(23):23917-23930. PubMed ID: 33237038
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic profiling and mRNA expression reveal candidate genes as biomarkers for colorectal cancer.
Zhang H; Dong S; Feng J
J Cell Biochem; 2019 Jun; 120(6):10767-10776. PubMed ID: 30672027
[TBL] [Abstract][Full Text] [Related]
16. Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer.
McDonald ME; Salinas EA; Devor EJ; Newtson AM; Thiel KW; Goodheart MJ; Bender DP; Smith BJ; Leslie KK; Gonzalez-Bosquet J
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866519
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines.
Houshdaran S; Hawley S; Palmer C; Campan M; Olsen MN; Ventura AP; Knudsen BS; Drescher CW; Urban ND; Brown PO; Laird PW
PLoS One; 2010 Feb; 5(2):e9359. PubMed ID: 20179752
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Kikuchi R; Tsuda H; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2007 Aug; 67(15):7095-105. PubMed ID: 17671176
[TBL] [Abstract][Full Text] [Related]
19. DNA Methylation Based Molecular Subtypes Predict Prognosis in Breast Cancer Patients.
Wu ZH; Tang Y; Zhou Y
Cancer Control; 2021; 28():1073274820988519. PubMed ID: 33504182
[TBL] [Abstract][Full Text] [Related]
20. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
